![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.60 | -2.91% | 20.00 | 20.00 | 20.90 | 20.60 | 20.00 | 20.60 | 34,413 | 16:24:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -500.00 | 89.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/3/2024 17:24 | I sat through what seemed to be a repeat of the 2023 presentation. Another year of investment/disposals and there will be jam tomorrow. Same old BATM they are utterly clueless | ![]() car1pet | |
13/3/2024 17:23 | Well I may be gullible but I was very impressed with what I heard. And confirmation that the clinical trials for Natlab were underway and would be completed end of year. Subject to them being successful it would be sold off or a JV probably next year. | ![]() resistance1 | |
13/3/2024 16:58 | Next one. Commercial cyber product ready end 2024. revenues forecast for 2025 | ![]() resistance1 | |
13/3/2024 16:55 | Key takeout of presentation 14 proof of concept Edgility trials running which range between $1m to $20m in size. They expect to get 7 Edgility contracts in 2024. Edgility very high margin. | ![]() resistance1 | |
12/3/2024 20:55 | Despite challenges, such as inflation impacting costs, year end results provide a positive outlook in my eyes. While results are steady, it is clear investors expect more. I am expecting the strategic shifts towards sales and marketing to drive revenue growth, with potential for acquisitions and sales in key areas like cybersecurity. | ![]() bigjon1 | |
12/3/2024 17:30 | Simon Thompson less bullish about BATM | ![]() car1pet | |
12/3/2024 17:28 | The technology group is focusing on its core cyber security, network solutions and diagnostics activities, but investors should wait before getting excited again March 12, 2024 by Simon Thompson Full-year cash profit up 12 per cent to $9.3mn Adjusted pre-tax profit up from $2.8mn to $4.8mn Potential for M&A activity and divestments Technology group BATM Advanced Communications (BVC:19.25p) is undergoing a corporate reorganisation, restructuring non-core activities and prioritising its core cyber security, network solutions and diagnostics activities. As part of the new strategy, the directors have engaged investment banks in both Israel and the US to explore corporate activity to add to the group’s capabilities, and to secure attractive terms for disposals. BATM closed the 2023 financial year with net cash of $31.7mn after deducting $4.5mn of lease liabilities and $4.6mn of bank debt, so has ample firepower available for acquisitions. It is also scaling up sales and marketing functions. In the short term, the increased investment will impact profit, hence why analysts at house broker Shore Capital reined in their 2024 cash profit estimate from $13.5mn to $9.4mn. This implies a flat performance year on year. However, analyst Robin Speakman notes that there is scope for “better forecast outcomes and so upgrades are also real and high from this point”. | ![]() car1pet | |
12/3/2024 17:03 | Cheers..it hasn’t proved one of his better tips but at least he is honest enough to keep following and updating. | ![]() kooba | |
12/3/2024 16:47 | Had a chance to look at these figures more in depth. The disappointing part is that whilst they are making progress its not what the market wanted to see. Networking is the weak component largely due to a massive and total shift in direction to platforms that are only starting to generate revenue. We knew revenue from Edgility would be anemic at first but it is a cumulative prospect. It would be nice to know the exact revenue specifically from Edgilty. The company has expanded its sales force to reflect this but the results will not hit the bottom line for a while. Also as earlier commented companies plan to upgrade edge/cloud platforms but financial constraints are slowing down end adoption. This is an area we need to see improvement and they seem critically aware of this. New more expansive Edgilty platform was launched this year the company has won numerous awards so they should be able to convert some of this. Cyber we knew the story here and there are plans to expand the offering so I would expect them to remain a bright sector for the foreseeable future. Medical/Diagnostics. I re read this several times and there are some very real positives here that are maybe not getting picked up on. Ex Covid sales were up 20.8% from last year and the company reports growth to be substantially up in H1/24 so this looks like a follow on trend. In addition MDX Lab was rolled out and is doing well. They plan to launch Extra lab NGS prep this year. These are expanded sales lines so they should boost 2024 sales. The medical diagnostics division looks in good shape. ADOR is being developed in tandem with Adaltis so there are expected spin offs for existing platforms and know how. RCA diagnostics is a very big deal and is very close to clinical trials. It is currently being trialled in University Hospital environment. They are still putting money into this so I feel that this is very much going forwards albeit slower than liked. Sales and Marketing expenses were up @2m Inventories were up 4m Payables were down 5m added link. | ![]() fse | |
12/3/2024 16:46 | I see Simon Thompson has done a piece today in the Investors Chronicle He rates it a Hold and like all of us here wants to see tangible results on the restructuring before getting excited. In the article there's some fresh insight on the divisional operations which he must have unearthed himself. | ![]() resistance1 | |
12/3/2024 15:50 | Just a recap on this time last year when they had just seriously downgraded the forecasts that have just been missed. Though the company does manage to make profit warnings sound positive ! ‘Therefore, we now expect revenue of c.$132m (-c.22% from our previous estimate but still implying c.13% growth yoy) and adj. PBT of c.$5.8m (-67% from our previous estimate but still implying increasing 3-fold yoy). We will look for confirm our forecasts shortly.” “Valuation thoughts: Based on our provisional forecast change, BATM trades on a FY23F PER of 47.5x and an EV/EBITDA of 9.4x but would expect multiples to fall significantly in FY24F. BATM is delivering strong underlying progress across the development of its technologies, these now visibly moving towards potential market inflection points, thus presenting a profitable high-growth opportunity across a span of technologies to investors. As underlying progress continues towards commercialisation, positive operating leverage to reported results should be expected in due course. “ Rinse and repeat. | ![]() kooba | |
12/3/2024 15:41 | Revenue came in as expected showing small increases in core business. Cyber was as we knew a bright spark and they are expanding their offering. The diagnostics business ex covid increased again. Edgility business is plodding along and revenue only starting to trickle in. This reflects what is going on in the market Edge solutions are a hot item but companies are lethargic in adopting and committing to the shift. More money was invested in ADOR and hopefully they can expand on what is going on here. It appears to be somewhat behind schedule although clinical trials could begin any day. Given the general backdrop results came in about as well as we could expect and less than hoped. | ![]() fse | |
12/3/2024 14:34 | They seem to have got Echo on board …a few to go. | ![]() kooba | |
12/3/2024 14:19 | Inflation impact on costs but not seen (positively) in revenues. Probably the nature of long term fixed price contracts with no clause for inflation. Anyway looking forward to see if my question tomorrow makes the cut. We all need reassurance that we will start to see the infamous 'inflection point' this year | ![]() resistance1 | |
12/3/2024 14:10 | Whilst we have cut the revenue and profitability figures we have done so positively. And not negatively/ Alrighty then. Very Barry-esque. | ![]() kemche | |
12/3/2024 14:01 | I had rather hoped the financials were kitchen sinked in 2022 after successive warnings and that 2023 might surprise on the upside alas more kitchen sinking before maybe they can beat expectation..how far does it have to drop to get a beat in ?? Just mentioning again the comments on inflationary impact on costs mentioned by the company..should there not be an inflationary impact on revenues?? Two sectors have seen falls in revenue. Anyway Shore Cap “Whilst we reduce our FY24F revenue and EBITDA forecasts from $153.6m and $13.5m respectively to $143.0m and $9.4m (by 7% and 30%, EBITDA reflecting operational gearing from sales & marketing investment, driving future growth), we feel that BATM is delivering on the promise it set out at last year's June Capital Markets Day, against a visibly challenging economic and geopolitical background. Given the nature of the Group's IP, addressing real-world acute needs, we believe that the scope for better forecast outcomes and so upgrades is also real and high from this point. We share BATM management's confidence in the outlook, therefore.” | ![]() kooba | |
12/3/2024 13:36 | The results don’t warrant a ‘joyous reception’ but they are steady. However for a growth company many expect more. The last 5-months (3 in the FY results) since October I’m sure hasn’t helped matters in terms of timelines for M&A/disposals but probably boosted Gov Cyber work. The Shore guidance seemed very positive in terms of the likelihood of upgrades. The share price will rocket with news of well priced disposals, networking contracts , M&A activity or dare I say ‘cherry picking’ approaches. For these reasons and many more, 2024 must deliver. | ![]() resistance1 | |
12/3/2024 13:21 | Where is the evidence of shorting ? It’s rather tricky evidencing such activity especially where a company has a dual listing as some trade imbalances could be resulting from arbitrage trades. Can you point to where one can check the apparently growing short position?? I personally don’t see any reason for a joyous reception to these results and there seems little in terms of potential news flow in the forward looking. Too much talk not enough delivery as always. | ![]() kooba | |
12/3/2024 13:14 | It's been going on for 18 months or so according to the daily share trades,I think the main shorter must read this board, they didn't like the comment about getting fingers burnt, since I posted theres been a pick up in shorting volume!! | ![]() gbenson1 | |
12/3/2024 13:06 | Gbenson there certainly seems to be some (short?) selling activity going on today a block of shares parcelled off into lots of small blocks to cause max impact. Good buying opportunity though. | ![]() resistance1 | |
12/3/2024 12:40 | Personal I think the company are running a tight ship in testing times, as a genuine investor I want to see a well run company with an increasing share price BATM has a large Spreadex 3%+ short and I guess others, on the company, and you can see them daily keeping the share price suppressed, no matter how well the company do they've got their hand tied behind their back. I'm sure the company although not admitting to it keep an eye on the share price I believe in restarting the share buyback will help to decrease the amount of free shares in circulation and increase the share price over time, these shorts need to have their fingers burnt big time!! | ![]() gbenson1 | |
12/3/2024 12:20 | Look, we could go back and forth on this stuff forever, kooba. I think I've been pretty clear on my position looking forward as far as the clear message(s) in these results that the company is serious about transitioning from an R&D to a sales/marketing focused company, supported by a now-delayed commitment to strategically focus on growth areas through disposals and/or targeted acquisitions. As for the delay in the latter, the war is a partial excuse, but BATM's size is also a factor. While I still expect some smaller deals, supported by their continued product and/or sales outperformance in Edge, Cyber and (don't shoot the messenger) ADOR, I increasingly think the management realise that much, much bigger, even transformational, deals are necessary and that will take a larger JV partner. We shall see | ![]() echoridge | |
12/3/2024 11:52 | I was hoping to see an acquisition in sales focused networking in US that they very much highlighted at the point of announcing the strategic review ..think that would have sent a clearer message of intent. Unfortunately the secondary businesses whilst not having the growth potential do provide a lump of profitable revenue , i am not sure though that these businesses will achieve what Batm might think is reasonable as they are a strange and diverse bag. One could see a big number for cyber to the right buyer as the sector is hot .. Financial Times: Israeli cybersecurity startup Wiz is in talks to raise funds at a valuation of more than $10bn. That is meant to be core but if one of these hyper funded ventures in the sector came knocking with some real money I’d imagine that could be hard to refuse. Something needs to happen because this is proving a very dull and disappointing counter ..we need action now and ideally some sales that show some momentum in Egility and some REALISTIC timelines for when ADOR might have a product to market. | ![]() kooba | |
12/3/2024 11:46 | Not really - bringing in banks to oversea M&A and possible sales.Not sure which comes first... | ![]() paulisi | |
12/3/2024 11:39 | If I'm right that this is the inflection point both in the business focus AS WELL AS the strategic review commitment-resulting | ![]() echoridge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions